TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of nonmyeloid malignancy~* Moderate to severe anemia~* Adequate iron stores as measured by either TSAT or ferritin~* About to start cycle of chemotherapy~* Eligible for epoetin alfa therapy~Exclusion Criteria:~* Highly elevated TSAT or ferritin~* Recent transfusion, epoetin alfa, darbepoetin or intravenous iron~* Medical conditions that would confound the efficacy evaluation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Induced Wound Healing by Application of Expanded Bone Marrow Stem Cells in Diabetic Patients With Critical Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes mellitus Type 1 or 2~* Peripheral occlusive arterial disease stage III or IV (Fontaine) with chronical ischemia, chronic foot ulcer, degree of severity \<5 (Wagner), older than 6 weeks, without acute wound infection~* Ulcer size 1 - 30cm2, in case of osteomyelitis only one bone should be affected no trend towards healing in the ulcer after one week of standard treatment~* Angiopathic or angioneuropathic diabetic foot syndrome with no possible option of operative or interventional revascularisation~* Age 18 - 80 years~* Declaration of patient consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: NO_INTERVENTION): patients received standard of care wound treatment according guideline of the American Diabetes Association (ADA)
- bone marrow stem cells intraarterial (Type: ACTIVE_COMPARATOR): bone marrow stem cells administered intraarterial
- tissue repair cells intramuscular (Type: ACTIVE_COMPARATOR): expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intramuscular
- tissue repair cells intraarterial (Type: ACTIVE_COMPARATOR): expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intraarterial
- bone marrow stem cells intramuscular (Type: ACTIVE_COMPARATOR): bone marrow stem cells administered intramuscular

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed SpA patients~* 18 years of age and older.~* Did not receive previous other biological treatments.~* Patients have at least 1 year on Enbrel.~Exclusion Criteria:~* Had previously used another biological treatments.~* Use of etanercept for less than 1 year duration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with spondyloarthropathies (Type: None): Patients with spondyloarthrosis that received Etanercept as treatment for disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent from the parents/guardians of the child before participating in the long-term follow-up.~* Subjects must have received their complete vaccination course according to the group allocation (i.e. subjects must have received either two doses of MMRV combined vaccine, or two doses of Priorix vaccine and one dose of Varilrix vaccine as separate injections in the primary vaccination study.~* Subjects were aged between 12 to 18 months of age at the time of the first vaccination in the primary study.~Exclusion Criteria:~* Subjects must not have received an additional dose of measles, mumps, rubella or varicella containing vaccines.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 or over~2. Ambulatory while taking 3,4-DAP, i.e. the patient was able to perform the timed up and go (TUG), either with or without an assistive device~3. Established diagnosis of LEMS, with documentation provided~4. Continuous use of Jacobus 3,4-DAP for at least 3 months~5. Minimum of 3 doses per day with no single dose less than 10 mg of 3,4-DAP~6. The patient needed to wait about 15 to 30 minutes to experience an unequivocal improvement in a LEMS-induced dysfunction after they take their first dose of 3,4-DAP in the morning \[a patient who remains in bed past this point by choice may still be eligible\]~7. Stable regimen of all LEMS-related treatments for at least 3 months~8. Stable daily regimen of other medications (prescription and over-the-counter) for a minimum of 1 month~9. Willing to chance being tapered off of 3,4-DAP~10. Fluency in English~11. If applicable, agreed to use birth control during heterosexual intercourse until at least 2 weeks after completion of study~12. A signed informed consent by the study subject~Exclusion Criteria:~1. Last monoclonal antibody treatment (e.g. rituximab) was less than 6 months ago (i.e., recent treatment is an exclusion)~2. Clinically significant or poorly controlled condition that in the opinion of the study personnel might pose an unacceptable risk to the patient if entered into the study~3. Respiratory failure requiring intubation while on 3,4-DAP with no precipitating event or medication~4. Use of any investigational drug other than 3,4-DAP within the last 30 days~5. Pregnant or lactating~6. Current use of other aminopyridines (e.g.4-AP) or guanidine~7. Did not display a sufficiently large response to 3,4-DAP during the baseline observation period in the CRU to detect a decline during withdrawal of 3,4-DAP

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous 3,4-DAP (Type: ACTIVE_COMPARATOR): Subjects continued taking their usual individualized regimen of 3,4-DAP base, 30 to 100 mg daily divided into at least 3 doses.
- Taper 3,4-DAP to Placebo (Type: PLACEBO_COMPARATOR): Subjects were tapered over 3 days from their usual individualized regimen of 3,4-DAP base (30 to 100 mg daily divided into at least 3 doses) to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TDCS for Auditory Hallucinations in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-55~* Structured Clinical Interview for DSM Disorders (SCID) primary diagnosis of DSM-IV (Diagnostic and Statistical Manual of Mental Disorders-Version IV) schizophrenia or schizoaffective disorder~* Persistent auditory verbal hallucinations~* Right handed~* Stable antipsychotic medication for \> 4 weeks~* Normal hearing~* If female and not infertile, must agree to use one of the following forms of contraception for the duration of study participation: systemic hormonal treatment, an interuterine device (IUD) which was implanted at least 2 months prior to screening, or double-barrier contraception~* Willing/capacity to provide informed consent~Exclusion Criteria:~* Substance dependence or abuse (excluding nicotine) in the past 90 days~* Current significant laboratory abnormality~* History of seizure, epilepsy in self or fist degree relatives, stroke, brain surgery, head injury with loss of consciousness \> 1 hour or clear cognitive sequelae, intracranial metal implants, known structural brain lesion, devices that may be affected by transcranial Direct Current Stimulation (tDCS) (pacemaker, medication pump, cochlear implant, implanted brain stimulator)~* Frequent and persistent migraines~* History of adverse reaction to neurostimulation or open skin wounds that would preclude safe placement of tDCS electrodes~* Participation in study of investigational medication/device within 4 weeks~* Current use of medications known to lower seizure threshold (lithium, serotonergic or tricyclic antidepressants)~* If female, pregnant or breast feeding at the time of screening~* For MRI study only: Claustrophobia or metal implants or paramagnetic objects contained within the body which may interfere with the MRI scan, as determined according to the guidelines set forth in the following reference book: Guide to MR procedures and metallic objects Shellock, PhD, Lippincott-Raven press, NY 1998

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Transcranial Direct Current Stimulation (Type: EXPERIMENTAL): Transcranial Direct Current Stimulation (tDCS) treatments will take place for 20 minutes per day for 5 consecutive days
- Sham tDCS (Type: SHAM_COMPARATOR): Sham tDCS(inactive)treatment (transcranial Direct Current Stimulation) will take place for 20 minutes per day for 5 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy-proven, previously untreated stage III or IV squamous cell carcinoma of the larynx, Primary tumor stage (T2, T3) and nodal stage (N0, N1, N2, N3).~* Measurable disease based on RECIST 1.1.~* Performance status 0 or 1 on Eastern Cooperative Oncology Group Performance Scale.~* Anticipated survival minimum of 12 months.~* Adequate labs~Exclusion Criteria:~* Patients with T1 primary tumor or T4 large volume tumor that has resulted in larynx dysfunction at baseline (for example tumor largely penetrating into base of tongue and resulting in inability to swallow at baseline)~* Prior radiation therapy to the larynx area or involved neck.~* Distant metastasis~* Known history of active tuberculosis (TB), autoimmune disease, pneumonitis, infection, HIV, Hepatitis B, or Hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pembrolizumab (Type: EXPERIMENTAL): Pembrolizumab every 3 weeks in combination with 7 weeks of radiation therapy and every 3 week cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 1) Meets Diagnostic and Statistical Manual -5 (DSM-5) criteria for opioid use disorder; (2) detained for at least 48 hours; (3) receiving opioid withdrawal treatment (as-usual) through the Detention Center's medical providers; (4) able and willing to provide informed consent in English; (5) detained for a charge that, if found guilty, will result in a sentence of less than 1 year; (6) plan to reside in Baltimore upon release; (7) 18 years of age and older.~Exclusion Criteria:~* (1) enrolled in methadone or buprenorphine treatment in the community at the time of arrest; (2) having a medical (liver failure, congestive heart failure) or psychiatric condition (e.g., suicidal ideation, psychosis) that would make participation unsafe in the judgment of the medical staff or the PI; (3) pregnancy; (4) allergy to methadone; and, (5) requiring treatment for alcohol or sedative hypnotic withdrawal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methadone plus Patient Navigation (Type: EXPERIMENTAL): Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
- Methadone (Type: EXPERIMENTAL): Participants will begin methadone during detention.
- Enhanced Treatment as Usual (Type: ACTIVE_COMPARATOR): Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males, and females not of child-bearing potential (surgically sterile or at least one year postmenopausal), of at least 50 years of age~* Probable Alzheimer's disease according to the NINCDS-ADRDA (National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association) and DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria~* MMSE (Mini-Mental State Examination) score of \> 10 and \< 26~* Patients initiating therapy for the first time with a cholinesterase inhibitor (patients prescribed both rivastigmine and memantine are allowed)~* Patients who failed to benefit from previous cholinesterase inhibitor treatment~Exclusion Criteria:~* Patients not treated according to the product monograph for rivastigmine capsules~* patients involved in a clinical trial~* Current diagnosis of an active skin lesion/disorder that would prevent accurate assessment of the adhesion and potential skin irritation of the patch (e.g., atopic dermatitis, wounded or scratched skin in the area of the patch application)~Other protocol-defined exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivastigmine 5 and 10 cm^2 patch (Type: EXPERIMENTAL): For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\^2 patch, with adjustments as necessary for safety and tolerability.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* One or both parents (according to local regulations) or a guardian must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study (If appropriate according to local regulations, the patient must also assent)~* Treated for schizophrenia, bipolar mania, autistic disorder, or conduct and other disruptive behavior disorders~* Had at least 6 months of exposure for an atypical antipsychotic drug within 24 months before the study visit (patients may or may not be taking the atypical antipsychotics at the time of actual enrollment, eligible patients can have exposure to multiple atypical antipsychotics, however, they cannot concomitantly be exposed to more than 1 atypical antipsychotic for a period of greater than 30 days)~* Had medical records or automated data available for at least 1 year prior to the start of exposure~* Height and weight were recorded at least once within 1 year before the start of exposure, and if available at any time points after the start of exposure in the medical records or electronic databases (not mandatory)~Exclusion Criteria:~* Have at least 1 medical record, at any time before the start of exposure, consistent with malignancy (other than non-melanoma skin cancer), pregnancy, or a developmental delay or abnormality associated with growth or sexual maturation delays not related to the specified indications~* Had exposure to prolactin elevating medications other than atypical antipsychotics and selective serotonin reuptake inhibitors (SSRIs)~* Had exposure to Paliperidone~* Cannot comply with study procedures

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Risperidone (Type: EXPERIMENTAL): Risperidone as per local prescribing practices
- Other atypical antipsychotic drugs (Type: EXPERIMENTAL): Other atypical antipsychotic drugs as per local prescribing practices

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of the Drug Therapy Versus Re-Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* history of symptomatic PAF~Exclusion Criteria:~* congestive heart failure~* LV ejection fraction \< 35%~* left atrial diameter \> 60 mm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AAD therapy (Type: ACTIVE_COMPARATOR): Recurrent episodes were pharmacologically managed by conventional AAD therapy (propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure) according to AF management guidelines.
- re-ablation procedure (Type: ACTIVE_COMPARATOR): Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s.~The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity. Only in patients with induced left atrial flutter, additional RF ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Varied Outreach Methods on Appointment Scheduling and Appointment Completion Using MyChart

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age 6-17 years~* has not had a well child check in past 365 days~* no future well child check visit scheduled~* parent preferred language = English or Spanish~Exclusion Criteria:~* no active MyChart account

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- No message (Type: PLACEBO_COMPARATOR): No message sent
- Standard message (Type: ACTIVE_COMPARATOR): 2 MyChart reminders that child is overdue for well child check visit
- Tailored message (Type: ACTIVE_COMPARATOR): 2 MyChart reminders that child is overdue for well child check visit with date of last WCC and age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete